Yang Qing-xu, Shao Chun-kui, Feng Zhi-Ying, Huang Ben-qiang, Han An-jia, Xiong Min, Zhao Wen-li, Wu Tong-tong
Department of Pathology, Central People's Hospital of Huizhou City, Huizhou 516001, China.
Di Yi Jun Yi Da Xue Xue Bao. 2005 Jun;25(6):678-81.
To investigate the value of detecting cytokeratin 19(CK19) and thyroperoxidase (TPO) expression in the diagnosis of thyroid diseases including thyroid carcinoma, multinodular goiter, adenoma and Hashimoto thyroiditis.
SP immunohistochemistry was used to detect the expressions of CK19 and TPO in paraffin-embedded thyroid tissue specimens obtained from 62 patients with thyroid carcinoma (30 with papillary carcinomas, 22 with follicular variant of papillary carcinomas, and 10 with follicular carcinomas) and 44 with benign thyroid diseases (including 22 with multinodular goiters, 14 with adenoma, and 8 with Hashimoto thyroiditis).
CK19 expression was detected in 96.8% of the thyroid carcinomas and in 4.5% of benign thyroid diseases, demonstrating a significant difference in CK19 expression between the two thyroid diseases (P<0.01). TPO expression was found in 100% of benign thyroid disease and in 3.2% of thyroid carcinoma, showing also a significant difference between them (P<0.01).
CK19 and TPO can be important molecular markers for diagnosing thyroid carcinoma.
探讨检测细胞角蛋白19（CK19）和甲状腺过氧化物酶（TPO）表达在甲状腺疾病（包括甲状腺癌、结节性甲状腺肿、腺瘤及桥本甲状腺炎）诊断中的价值。
采用SP免疫组织化学法检测62例甲状腺癌患者（30例乳头状癌、22例乳头状癌滤泡状变异型、10例滤泡状癌）及44例良性甲状腺疾病患者（包括22例结节性甲状腺肿、14例腺瘤、8例桥本甲状腺炎）石蜡包埋甲状腺组织标本中CK19和TPO的表达。
96.8%的甲状腺癌患者检测到CK19表达，而良性甲状腺疾病患者中该比例为4.5%，两种甲状腺疾病的CK19表达存在显著差异（P<0.01）。100%的良性甲状腺疾病患者检测到TPO表达，而甲状腺癌患者中该比例为3.2%，两者也存在显著差异（P<0.01）。
CK19和TPO可作为诊断甲状腺癌的重要分子标志物。
